Description
Irinotecan Amaxa Concentrate for Infusions 20 mg/ml. 15 ml. (300 mg.) №1
Ingredients:
Each ml contains 20 mg of Irinotecan hydrochloride trihydrate as the active ingredient.
Mechanism of Action:
Irinotecan exerts its pharmacological effects by inhibiting topoisomerase I enzyme, leading to the formation of DNA strand breaks and ultimately inducing cell death.
Pharmacological Properties:
Irinotecan is a cytotoxic agent that belongs to the class of topoisomerase inhibitors. It is a prodrug that is converted to its active form SN-38 in the body, exerting its antitumor activity.
Indications for Use:
Irinotecan Amaxa concentrate for infusions is indicated for the treatment of advanced colorectal cancer and small cell lung cancer in patients who have failed first-line chemotherapy.
Contraindications:
Contraindications include a history of severe hypersensitivity reactions to Irinotecan or any components of the formulation. It should not be used in patients with a deficiency in the UGT1A1 enzyme.
Side Effects:
Common side effects of Irinotecan include diarrhea, myelosuppression, nausea, vomiting, and alopecia. Patients may also experience infusion site reactions and fatigue.
Usage Instructions:
Irinotecan Amaxa concentrate for infusions should be diluted and administered intravenously over a specific duration as directed by a qualified healthcare provider. Dosage is individualized based on the patient’s body surface area and overall health status.
Benefits Compared to Analogues:
Compared to traditional chemotherapy agents, Irinotecan has shown improved efficacy in certain cancer types and has demonstrated a favorable safety profile in clinical trials.
Suitable Patient Groups:
Irinotecan can be used in adult patients with advanced colorectal cancer or small cell lung cancer. Dosing adjustments may be required for elderly patients or those with renal or hepatic impairment.
Storage Conditions and Shelf Life:
Irinotecan Amaxa concentrate should be stored according to the manufacturer’s instructions, typically at controlled room temperature. The shelf life of the product should be checked before each use.
Packaging Description:
The product is supplied as a 15 ml vial containing 300 mg of Irinotecan Amaxa concentrate for infusions. Each vial is labeled with the necessary information for proper identification.
Clinical Evidence and Proven Effectiveness:
Irinotecan has been extensively studied in clinical trials, demonstrating significant efficacy in prolonging progression-free survival and overall survival in patients with advanced colorectal cancer and small cell lung cancer.
